Male Obesity-related Secondary Hypogonadism - Pathophysiology, Clinical Implications and Management

Overview

Journal Eur Endocrinol

Specialty Endocrinology

Date 2019 Oct 17

PMID 31616498

Citations 42

Authors

Cornelius J Fernandez

Elias C Chacko

Joseph M Pappachan

Affiliations

Soon will be listed here.

Abstract

The single most significant risk factor for testosterone deficiency in men is obesity. The pathophysiological mechanisms involved in male obesity-related secondary hypogonadism are highly complex. Obesity-induced increase in levels of leptin, insulin, proinflammatory cytokines and oestrogen can cause a functional hypogonadotrophic hypogonadism with the defect present at the level of the hypothalamic gonadotrophin-releasing hormone (GnRH) neurons. The resulting hypogonadism by itself can worsen obesity, creating a self-perpetuating cycle. Obesity-induced hypogonadism is reversible with substantial weight loss. Lifestyle-measures form the cornerstone of management as they can potentially improve androgen deficiency symptoms irrespective of their effect on testosterone levels. In selected patients, bariatric surgery can reverse the obesity-induced hypogonadism. If these measures fail to relieve symptoms and to normalise testosterone levels, in appropriately selected men, testosterone replacement therapy could be started. Aromatase inhibitors and selective oestrogen receptor modulators are not recommended due to lack of consistent clinical trial-based evidence.

Citing Articles

Association between C-reactive protein-triglyceride glucose index and testosterone levels among adult men: analyses of NHANES 2015-2016 data.

Zhang B, Gu Y, Chen Y, Xia W, Shao N, Zhuang Q Sex Med. 2025; 13(1):qfaf012.

PMID: 40061443 PMC: 11890278. DOI: 10.1093/sexmed/qfaf012.

Impact of Sexual Dimorphism on Therapy Response in Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease: From Conventional and Nutritional Approaches to Emerging Therapies.

Dileo E, Saba F, Parasiliti-Caprino M, Rosso C, Bugianesi E Nutrients. 2025; 17(3).

PMID: 39940335 PMC: 11821005. DOI: 10.3390/nu17030477.

Impact of Weight Loss on Testosterone Levels: A Review of BMI and Testosterone.

Okobi O, Khoury P, De la Vega R, Figueroa R, Desai D, Mangiliman B Cureus. 2025; 16(12):e76139.

PMID: 39840189 PMC: 11745839. DOI: 10.7759/cureus.76139.

Definition and diagnostic criteria of clinical obesity.

Rubino F, Cummings D, Eckel R, Cohen R, Wilding J, Brown W Lancet Diabetes Endocrinol. 2025; 13(3):221-262.

PMID: 39824205 PMC: 11870235. DOI: 10.1016/S2213-8587(24)00316-4.

Association of total testosterone levels with cardiometabolic diseases in men with erectile dysfunction.

Chen B, Tsai P, Jiann B Sex Med. 2025; 12(6):qfae089.

PMID: 39801930 PMC: 11723798. DOI: 10.1093/sexmed/qfae089.

References

Yamazaki H, Kushiyama A, Sakoda H, Fujishiro M, Yamamotoya T, Nakatsu Y . Protective Effect of Sex Hormone-Binding Globulin against Metabolic Syndrome: Evidence Showing Anti-Inflammatory and Lipolytic Effects on Adipocytes and Macrophages. Mediators Inflamm. 2018; 2018:3062319. PMC: 6036814. DOI: 10.1155/2018/3062319. View

Esposito K, Giugliano F, Di Palo C, Giugliano G, Marfella R, DAndrea F . Effect of lifestyle changes on erectile dysfunction in obese men: a randomized controlled trial. JAMA. 2004; 291(24):2978-84. DOI: 10.1001/jama.291.24.2978. View

George J, Millar R, Anderson R . Hypothesis: kisspeptin mediates male hypogonadism in obesity and type 2 diabetes. Neuroendocrinology. 2010; 91(4):302-7. DOI: 10.1159/000299767. View

Laaksonen D, Niskanen L, Punnonen K, Nyyssonen K, Tuomainen T, Valkonen V . The metabolic syndrome and smoking in relation to hypogonadism in middle-aged men: a prospective cohort study. J Clin Endocrinol Metab. 2004; 90(2):712-9. DOI: 10.1210/jc.2004-0970. View

Saboor Aftab S, Kumar S, Barber T . The role of obesity and type 2 diabetes mellitus in the development of male obesity-associated secondary hypogonadism. Clin Endocrinol (Oxf). 2012; 78(3):330-7. DOI: 10.1111/cen.12092. View

Morelli A, Sarchielli E, Comeglio P, Filippi S, Vignozzi L, Marini M . Metabolic syndrome induces inflammation and impairs gonadotropin-releasing hormone neurons in the preoptic area of the hypothalamus in rabbits. Mol Cell Endocrinol. 2013; 382(1):107-119. DOI: 10.1016/j.mce.2013.09.017. View

Fui M, Hoermann R, Zajac J, Grossmann M . The effects of testosterone on body composition in obese men are not sustained after cessation of testosterone treatment. Clin Endocrinol (Oxf). 2017; 87(4):336-343. DOI: 10.1111/cen.13385. View

Khoo J, Tian H, Tan B, Chew K, Ng C, Leong D . Comparing effects of low- and high-volume moderate-intensity exercise on sexual function and testosterone in obese men. J Sex Med. 2013; 10(7):1823-32. DOI: 10.1111/jsm.12154. View

Corona G, Rastrelli G, Morgentaler A, Sforza A, Mannucci E, Maggi M . Meta-analysis of Results of Testosterone Therapy on Sexual Function Based on International Index of Erectile Function Scores. Eur Urol. 2017; 72(6):1000-1011. DOI: 10.1016/j.eururo.2017.03.032. View

10.

Saad F, Yassin A, Doros G, Haider A . Effects of long-term treatment with testosterone on weight and waist size in 411 hypogonadal men with obesity classes I-III: observational data from two registry studies. Int J Obes (Lond). 2015; 40(1):162-70. PMC: 4722240. DOI: 10.1038/ijo.2015.139. View

11.

Hu T, Chen Y, Lin P, Shih C, Bai C, Yuan K . Testosterone-Associated Dietary Pattern Predicts Low Testosterone Levels and Hypogonadism. Nutrients. 2018; 10(11). PMC: 6266690. DOI: 10.3390/nu10111786. View

12.

Corona G, Rastrelli G, Monami M, Saad F, Luconi M, Lucchese M . Body weight loss reverts obesity-associated hypogonadotropic hypogonadism: a systematic review and meta-analysis. Eur J Endocrinol. 2013; 168(6):829-43. DOI: 10.1530/EJE-12-0955. View

13.

Wang N, Zhai H, Han B, Li Q, Chen Y, Chen Y . Visceral fat dysfunction is positively associated with hypogonadism in Chinese men. Sci Rep. 2016; 6:19844. PMC: 4726157. DOI: 10.1038/srep19844. View

14.

Dimitriadis G, Randeva H, Aftab S, Ali A, Hattersley J, Pandey S . Metabolic phenotype of male obesity-related secondary hypogonadism pre-replacement and post-replacement therapy with intra-muscular testosterone undecanoate therapy. Endocrine. 2018; 60(1):175-184. PMC: 5845623. DOI: 10.1007/s12020-017-1516-x. View

15.

Magnussen L, Andersen P, Diaz A, Ostojic J, Hojlund K, Hougaard D . MR spectroscopy of hepatic fat and adiponectin and leptin levels during testosterone therapy in type 2 diabetes: a randomized, double-blinded, placebo-controlled trial. Eur J Endocrinol. 2017; 177(2):157-168. DOI: 10.1530/EJE-17-0071. View

16.

Wallis C, Lo K, Lee Y, Krakowsky Y, Garbens A, Satkunasivam R . Survival and cardiovascular events in men treated with testosterone replacement therapy: an intention-to-treat observational cohort study. Lancet Diabetes Endocrinol. 2016; 4(6):498-506. DOI: 10.1016/S2213-8587(16)00112-1. View

17.

Camacho E, Huhtaniemi I, ONeill T, Finn J, Pye S, Lee D . Age-associated changes in hypothalamic-pituitary-testicular function in middle-aged and older men are modified by weight change and lifestyle factors: longitudinal results from the European Male Ageing Study. Eur J Endocrinol. 2013; 168(3):445-55. DOI: 10.1530/EJE-12-0890. View

18.

Boonchaya-Anant P, Laichuthai N, Suwannasrisuk P, Houngngam N, Udomsawaengsup S, Snabboon T . Changes in Testosterone Levels and Sex Hormone-Binding Globulin Levels in Extremely Obese Men after Bariatric Surgery. Int J Endocrinol. 2016; 2016:1416503. PMC: 5048048. DOI: 10.1155/2016/1416503. View

19.

Hayes L, Elliott B . Short-Term Exercise Training Inconsistently Influences Basal Testosterone in Older Men: A Systematic Review and Meta-Analysis. Front Physiol. 2019; 9:1878. PMC: 6339914. DOI: 10.3389/fphys.2018.01878. View

20.

Caprio M, Isidori A, Carta A, Moretti C, Dufau M, Fabbri A . Expression of functional leptin receptors in rodent Leydig cells. Endocrinology. 1999; 140(11):4939-47. DOI: 10.1210/endo.140.11.7088. View